Free Trial
NYSE:ITGR

Integer Q2 2025 Earnings Report

Integer logo
$112.07 -2.57 (-2.24%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Integer EPS Results

Actual EPS
N/A
Consensus EPS
$1.57
Beat/Miss
N/A
One Year Ago EPS
N/A

Integer Revenue Results

Actual Revenue
N/A
Expected Revenue
$464.37 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Integer Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 24, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Integer Earnings Headlines

Brokerages Set Integer Holdings Corporation (NYSE:ITGR) PT at $145.00
Integer Holdings (ITGR) Gets a Buy from Citi
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
Integer Appoints Michael Coyle to Board of Directors
See More Integer Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integer? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integer and other key companies, straight to your email.

About Integer

Integer (NYSE:ITGR) (NYSE: ITGR) is a global provider of outsourced medical device product development and manufacturing services. The company specializes in the design, engineering and production of complex electromechanical and digital systems for a wide range of implantable and non-implantable medical devices. Integer’s solutions support cardiovascular, neuromodulation, drug delivery, orthopedic, biosurgery and general surgery applications, helping original equipment manufacturers (OEMs) accelerate innovation and time to market.

Integer operates through two primary business segments. The Technology & Services Solutions (TSS) segment delivers comprehensive, end-to-end services including design for manufacturability, rapid prototyping, clinical trial support, and final production of non-implantable devices such as infusion pumps and surgical instruments. The Implantable Solutions Group (ISG) focuses on precision manufacturing of implantable components—battery separators, lead connectors, sensors and sub-assemblies—for pacemakers, defibrillators, neurostimulators and related therapies.

Founded in the early 1970s under the name Greatbatch by Dr. Wilson Greatbatch, an inventor best known for his work on the cardiac pacemaker, the company has evolved through strategic acquisitions and organic growth. A landmark transaction in 2014 brought Bal Seal Engineering’s precision fluid management components into the fold, while the name change to Integer in 2016 reflected the company’s broader scope across the medical device supply chain. Subsequent investments have further expanded capability in drug-coating technologies, miniaturization and advanced materials.

Integer serves a diversified, blue-chip customer base of medical device OEMs in North America, Europe, Asia-Pacific and Latin America. The company maintains manufacturing and design centers in the United States, Costa Rica, Puerto Rico, the Netherlands, Ireland, India, China, Japan, Germany and Mexico. Under the leadership of President and Chief Executive Officer Scott W. Drake, Integer continues to broaden its engineering expertise and global manufacturing footprint, enabling medical technology companies to bring safer, more effective devices to patients worldwide.

View Integer Profile

More Earnings Resources from MarketBeat